Literature DB >> 29807795

Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells.

Young Hwan Kim1, Yae Jin Yoon2, Yu-Jin Lee2, Cheol-Hee Kim3, Sangku Lee2, Dong Ho Choung2, Dong Cho Han4, Byoung-Mog Kwon5.   

Abstract

Piperlongumine (PL), isolated from Piper longum L., is receiving intense interest due to its selectively ability to kill cancer cells but not normal cells. We synthesized a number of analogues by replacing the cyclic amide of PL with aliphatic amides to explore structural diversity. Compound CG-06 had the strongest cytotoxic profile of this series, showing potent effects in human prostate cancer DU-145 cells, in which signal transducer and activator of transcription 3 (STAT3) is constitutively active. CG-06 inhibited STAT3 phosphorylation at tyrosine 705 in a dose- and time dependent manner in DU-145 cells and suppressed IL-6-induced STAT3 phosphorylation at Tyr-705 in DU-145 and LNCaP cell lines. CG-06 decreased the expression levels of STAT3 target genes, such as cyclin A, Bcl-2, and survivin. Notably, we used drug affinity responsive target stability (DARTS) to show that CG-06 binds directly to STAT3, and the reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC) rescued the CG-06-induced suppression p-STAT3. Our results suggest that CG-06 is a novel inhibitor of STAT3 and may be a useful lead molecule for the development of a therapeutic STAT3 inhibitor.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Piperlongumine; Prostate cancer; ROS; STAT3

Mesh:

Substances:

Year:  2018        PMID: 29807795     DOI: 10.1016/j.bmcl.2018.05.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS-STAT3 pathway.

Authors:  Di Chen; Xinyue Wei; Ke Yang; Xinyue Liu; Yujin Song; Futing Bai; Yi Jiang; Yuhang Guo; Rajiv Kumar Jha
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.573

2.  Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells.

Authors:  Li Zhou; Ming Li; Xinyou Yu; Feng Gao; Wei Li
Journal:  Int J Biol Sci       Date:  2019-03-01       Impact factor: 6.580

Review 3.  The promising potential of piperlongumine as an emerging therapeutics for cancer.

Authors:  Dey Parama; Varsha Rana; Sosmitha Girisa; Elika Verma; Uzini Devi Daimary; Krishan Kumar Thakur; Aviral Kumar; Ajaikumar B Kunnumakkara
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30

Review 4.  STAT3 and Its Pathways' Dysregulation-Underestimated Role in Urological Tumors.

Authors:  Maciej Golus; Piotr Bugajski; Joanna Chorbińska; Wojciech Krajewski; Artur Lemiński; Jolanta Saczko; Julita Kulbacka; Tomasz Szydełko; Bartosz Małkiewicz
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.